Catalyst Wire Dossier Catalyst Wire Dossier

Necitumumab (Portrazza)

necitumumab · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Necitumumab (Portrazza), covering 2016-06-27 to 2016-06-27. Get the full timeline:

Most recent: Clinical Trial Update: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin [Phase 3]

See pricing